menu search

GNCA / Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting
Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea's neoantigen-targeted peripheral T cell therapy for solid tumors Read More
Posted: Mar 8 2022, 17:39
Author Name: GlobeNewsWire
Views: 122412

GNCA News  

Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes

By PennyStocks
April 11, 2022

Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes

What you need to know about trading penny stocks on April 11th The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes  appeared firs more_horizontal

Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients

By Benzinga
April 8, 2022

Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients

Genocea Biosciences Inc (NASDAQ: GNCA) has shared initial data from Phase 1/2a TiTAN trial OF GEN-011 in patients with refractory solid tumors. The more_horizontal

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference

By GlobeNewsWire
March 14, 2022

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference

CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation more_horizontal

Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 10, 2022

Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript

Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript more_horizontal

Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

By GlobeNewsWire
March 8, 2022

Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea's neoantigen-targeted peripheral T cell therapy for solid t more_horizontal

Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference

By GlobeNewsWire
February 10, 2022

Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation n more_horizontal

Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference

By GlobeNewsWire
February 10, 2022

Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation n more_horizontal

Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference

By GlobeNewsWire
February 10, 2022

Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation n more_horizontal


Search within

Pages Search Results: